

Participant Summary
MONTH 3 OF YEAR 2026

ANALYTE			SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)						
080 FIBRINOGEN			CLIA TEST ID #: 825		EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-161	69	DIAG.STAGO	85	STA FIBRI		11	263.455	18.529	7.03	211.000	316.000
2026-161	73	ACL 8 TO E	87	HEMOSIL-C		10	278.700	8.186	2.94	223.000	334.000
2026-161	79	CS-2500	67	DADE		14	226.357	13.489	5.96	181.000	272.000
2026-162	69	DIAG.STAGO	85	STA FIBRI		11	288.182	21.109	7.32	231.000	346.000
2026-162	73	ACL 8 TO E	87	HEMOSIL-C		10	302.200	13.862	4.59	242.000	363.000
2026-162	79	CS-2500	67	DADE		14	246.500	19.085	7.74	197.000	296.000
2026-163	69	DIAG.STAGO	85	STA FIBRI		11	509.091	36.610	7.19	407.000	611.000
2026-163	73	ACL 8 TO E	87	HEMOSIL-C		10	521.300	22.694	4.35	417.000	626.000
2026-163	79	CS-2500	67	DADE		14	457.769	13.033	2.85	366.000	549.000
2026-164	69	DIAG.STAGO	85	STA FIBRI		11	152.091	9.120	6.00	122.000	183.000
2026-164	73	ACL 8 TO E	87	HEMOSIL-C		10	155.100	6.745	4.35	124.000	186.000
2026-164	79	CS-2500	67	DADE		14	126.429	9.202	7.28	101.000	152.000
2026-165	69	DIAG.STAGO	85	STA FIBRI		11	271.909	17.511	6.44	218.000	326.000
2026-165	73	ACL 8 TO E	87	HEMOSIL-C		10	280.700	14.248	5.08	225.000	337.000
2026-165	79	CS-2500	67	DADE		14	232.571	17.203	7.40	186.000	279.000
081 PART.THROM. TIME-PTT			CLIA TEST ID #: 835		EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-161	62	DADE SYS.	35	DADE ACTIN		61	35.363	1.832	5.18	30.100	40.700
2026-161	69	DIAG.STAGO	49	STA-PTT		23	38.317	1.258	3.28	32.600	44.100
2026-161	73	ACL 8 TO E	56	PTT-HEMO		27	36.893	0.876	2.37	31.400	42.400
2026-161	76	STAGO STAR	49	STA-PTT		19	38.842	2.779	7.16	33.000	44.700
2026-161	79	CS-2500	35	DADE ACTIN		16	37.169	0.534	1.44	31.600	42.700
2026-162	62	DADE SYS.	35	DADE ACTIN		61	27.263	0.793	2.91	23.200	31.400
2026-162	69	DIAG.STAGO	49	STA-PTT		23	30.435	0.695	2.28	25.900	35.000

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-162	73	ACL 8 TO E	56 PTT-HEMO	27	29.800	0.834	2.80	25.300	34.300	
2026-162	76	STAGO STAR	49 STA-PTT	19	29.726	1.756	5.91	25.300	34.200	
2026-162	79	CS-2500	35 DADE ACTIN	16	28.094	0.404	1.44	23.900	32.300	
081	PART.THROM. TIME-PTT		CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-163	62	DADE SYS.	35 DADE ACTIN	61	25.980	0.657	2.53	22.100	29.900	
2026-163	69	DIAG.STAGO	49 STA-PTT	23	28.991	0.803	2.77	24.600	33.300	
2026-163	73	ACL 8 TO E	56 PTT-HEMO	27	35.096	1.209	3.45	29.800	40.400	
2026-163	76	STAGO STAR	49 STA-PTT	19	28.716	1.536	5.35	24.400	33.000	
2026-163	79	CS-2500	35 DADE ACTIN	16	26.288	0.523	1.99	22.300	30.200	
2026-164	62	DADE SYS.	35 DADE ACTIN	61	26.400	1.066	4.04	22.400	30.400	
2026-164	69	DIAG.STAGO	49 STA-PTT	23	29.791	0.970	3.26	25.300	34.300	
2026-164	73	ACL 8 TO E	56 PTT-HEMO	27	28.200	0.518	1.84	24.000	32.400	
2026-164	76	STAGO STAR	49 STA-PTT	19	29.389	1.825	6.21	25.000	33.800	
2026-164	79	CS-2500	35 DADE ACTIN	16	27.340	0.206	0.75	23.200	31.400	
2026-165	62	DADE SYS.	35 DADE ACTIN	61	41.108	2.838	6.90	34.900	47.300	
2026-165	69	DIAG.STAGO	49 STA-PTT	23	44.652	1.806	4.04	38.000	51.400	
2026-165	73	ACL 8 TO E	56 PTT-HEMO	27	45.085	1.114	2.47	38.300	51.800	
2026-165	76	STAGO STAR	49 STA-PTT	19	44.316	2.225	5.02	37.700	51.000	
2026-165	79	CS-2500	35 DADE ACTIN	16	43.219	0.601	1.39	36.700	49.700	
082	PROTHROMBIN TIME(P.T)		CLIA TEST ID #: 845							
2026-161	62	DADE SYS.	33 DADE INNOV	62	18.560	0.670	3.61	15.800	21.300	
2026-161	69	DIAG.STAGO	44 STA NEO CI	13	23.985	0.580	2.42	20.400	27.600	
2026-161	73	ACL 8 TO E	41 HEMOSIL RE	25	20.564	0.689	3.35	17.500	23.600	
2026-161	76	STAGO STAR	44 STA NEO CI	12	24.292	1.155	4.75	20.600	27.900	
2026-161	79	CS-2500	33 DADE INNOV	17	18.553	0.394	2.12	15.800	21.300	
2026-162	62	DADE SYS.	33 DADE INNOV	62	10.250	0.342	3.34	8.700	11.800	
2026-162	69	DIAG.STAGO	44 STA NEO CI	13	13.315	0.282	2.12	11.300	15.300	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-162	73	ACL 8 TO E	41	HEMOSIL RE	25	11.192	0.210	1.87	9.500	12.900	
2026-162	76	STAGO STAR	44	STA NEO CI	12	12.700	0.532	4.19	10.800	14.600	
2026-162	79	CS-2500	33	DADE INNOV	17	10.812	0.261	2.41	9.200	12.400	
082 PROTHROMBIN TIME(PT)			CLIA TEST ID #: 845		EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-163	62	DADE SYS.	33	DADE INNOV	62	10.867	0.392	3.61	9.200	12.500	
2026-163	69	DIAG.STAGO	44	STA NEO CI	13	14.031	0.395	2.81	11.900	16.100	
2026-163	73	ACL 8 TO E	41	HEMOSIL RE	25	11.296	0.193	1.71	9.600	13.000	
2026-163	76	STAGO STAR	44	STA NEO CI	12	13.508	0.550	4.07	11.500	15.500	
2026-163	79	CS-2500	33	DADE INNOV	17	11.259	0.322	2.86	9.600	12.900	
2026-164	62	DADE SYS.	33	DADE INNOV	62	11.987	0.416	3.47	10.200	13.800	
2026-164	69	DIAG.STAGO	44	STA NEO CI	13	14.938	0.379	2.54	12.700	17.200	
2026-164	73	ACL 8 TO E	41	HEMOSIL RE	25	12.844	0.294	2.29	10.900	14.800	
2026-164	76	STAGO STAR	44	STA NEO CI	12	14.442	0.692	4.79	12.300	16.600	
2026-164	79	CS-2500	33	DADE INNOV	17	12.488	0.219	1.76	10.600	14.400	
2026-165	62	DADE SYS.	33	DADE INNOV	62	25.725	1.261	4.90	21.900	29.600	
2026-165	69	DIAG.STAGO	44	STA NEO CI	13	32.646	0.904	2.77	27.700	37.500	
2026-165	73	ACL 8 TO E	41	HEMOSIL RE	25	28.912	1.103	3.82	24.600	33.200	
2026-165	76	STAGO STAR	44	STA NEO CI	12	33.242	2.150	6.47	28.300	38.200	
2026-165	79	CS-2500	33	DADE INNOV	17	25.465	0.961	3.77	21.600	29.300	

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 100 HEMA. CELL IDENTIFI.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2026-111					017 017		001 - BLAST	925	1	922	0
2026-111					017 017		014 - LYMPHOCYTE	925	1	922	0
2026-111					017 017		017 - MONOCYTE	925	922	922	100
2026-111					017 017		003 - MYELOCYTE	925	1	922	0
2026-112					067 067		038 - HOWELL-JOL	925	1	920	0
2026-112					067 067		067 - CABOT RING	925	920	920	100
2026-112					067 067		070 - Plasmodium	925	4	920	0
2026-113					073 073		030 - ERYTHROCYT	925	1	915	0
2026-113					073 073		033 - POLYCHROMA	925	5	915	0
2026-113					073 073		036 - BASOPHILIC	925	3	915	0
2026-113					073 073		073 - RETICULOCY	925	915	915	100
2026-113					073 073		074 - BLUE-GREEN	925	1	915	0
2026-114					001 001		013 - LYMPHOCYTE	925	100	776	0
2026-114					001 001		001 - BLAST	925	776	776	100
2026-114					001 001		014 - LYMPHOCYTE	925	18	776	0
2026-114					001 001		016 - PLASMACYTE	925	2	776	0
2026-114					001 001		002 - PROMYELOCY	925	5	776	0
2026-114					001 001		003 - MYELOCYTE	925	8	776	0
2026-114					001 001		069 - Prolymphoc	925	16	776	0
2026-115					011 011		011 - HYPERSEGME	925	919	919	100
2026-115					011 011		006 - SEGMENTED	925	6	919	0

Participant Summary
MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 137 RETICULOCYTE COUNT						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{GREATER}				
2026-141	7	M.B.MANUAL		11	1.618	0.409	25.25	0.400	2.800	
2026-141	24	Unicel DxH		12	0.858	0.166	19.30	0.400	1.400	
2026-141	25	SYSMEX XN		38	0.774	0.088	11.36	0.500	1.000	
2026-142	7	M.B.MANUAL		11	6.136	0.944	15.39	3.300	9.000	
2026-142	24	Unicel DxH		12	3.725	0.866	23.25	1.100	6.300	
2026-142	25	SYSMEX XN		38	2.042	0.567	27.76	0.300	3.700	
2026-143	7	M.B.MANUAL		11	10.045	1.574	15.67	5.300	14.800	
2026-143	24	Unicel DxH		12	7.883	0.962	12.21	5.000	10.800	
2026-143	25	SYSMEX XN		38	3.224	1.524	47.28	0	7.800	
2026-144	7	M.B.MANUAL		11	6.073	1.223	20.13	2.400	9.700	
2026-144	24	Unicel DxH		12	3.683	1.004	27.26	0.700	6.700	
2026-144	25	SYSMEX XN		38	2.050	0.550	26.81	0.400	3.700	
2026-145	7	M.B.MANUAL		11	1.445	0.246	17.04	0.700	2.200	
2026-145	24	Unicel DxH		12	0.842	0.138	16.42	0.400	1.300	
2026-145	25	SYSMEX XN		38	0.779	0.086	11.08	0.500	1.000	

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
153	SED. RATE (ESR)		EVALUATION CRITERIA: TARGET VALUE	3	SD OR 35 %	{GREATER}				
2026-151	4	SEDIPLAST		636	35.887	5.889	16.41	18.000	54.000	
2026-151	10	SEDI RATE		59	35.138	6.293	17.91	16.000	54.000	
2026-151	11	SEDIMAT-15		43	118.093	15.595	13.21	71.000	165.000	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-151	14	GLOBAL SC.		10	35.700	8.649	24.23	10.000	62.000	
2026-151	19	MINI CUBE		53	35.942	12.437	34.60	0	73.000	
2026-151	20	SEDiREDi		17	35.235	9.372	26.60	7.000	63.000	
153 SED. RATE (ESR)				CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}						
2026-152	4	SEDIPLAST		637	36.406	6.044	16.60	18.000	55.000	
2026-152	10	SEDI RATE		59	35.695	6.649	18.63	16.000	56.000	
2026-152	11	SEDIMAT-15		43	115.558	19.869	17.19	56.000	175.000	
2026-152	14	GLOBAL SC.		10	33.200	6.524	19.65	14.000	53.000	
2026-152	19	MINI CUBE		53	40.885	17.751	43.42	0	94.000	
2026-152	20	SEDiREDi		17	32.529	7.089	21.79	11.000	54.000	
2026-153	4	SEDIPLAST		637	5.582	1.774	31.77	0.000	11.000	
2026-153	10	SEDI RATE		59	6.492	1.750	26.96	1.000	12.000	
2026-153	11	SEDIMAT-15		43	5.238	3.115	59.47	0	15.000	
2026-153	14	GLOBAL SC.		10	7.200	1.470	20.41	3.000	12.000	
2026-153	19	MINI CUBE		53	13.288	2.051	15.43	7.000	19.000	
2026-153	20	SEDiREDi		17	7.118	0.676	9.50	5.000	10.000	
2026-154	4	SEDIPLAST		637	5.876	2.672	45.48	0	14.000	
2026-154	10	SEDI RATE		59	6.379	1.710	26.81	1.000	12.000	
2026-154	11	SEDIMAT-15		43	7.614	4.942	64.90	0	22.000	
2026-154	14	GLOBAL SC.		10	7.500	1.565	20.87	3.000	12.000	
2026-154	19	MINI CUBE		53	13.481	2.098	15.57	7.000	20.000	
2026-154	20	SEDiREDi		17	7.353	0.836	11.37	5.000	10.000	
2026-155	4	SEDIPLAST		637	36.440	6.165	16.92	18.000	55.000	
2026-155	10	SEDI RATE		59	35.224	6.192	17.58	17.000	54.000	
2026-155	11	SEDIMAT-15		43	122.442	13.862	11.32	80.000	165.000	
2026-155	14	GLOBAL SC.		10	32.500	7.813	24.04	9.000	56.000	
2026-155	19	MINI CUBE		53	43.500	13.806	31.74	2.000	85.000	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL			GRP: 138 SED. RATE (ESR)						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2026-155	20	SEDiREDi		17	31.647	4.690	14.82	18.000	46.000			

SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL			GRP: 125 DIFF. FOR 5 PAR NEW						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
172	DIFF. WBC FOR 5 PAR.	CLIA TEST ID #: 770	EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2026131X	1	SYSMEX CBC	1 NEUTROPHIL	25	XS SERIES	137	49.689	1.640	3.30	37.300	62.100	
2026131X	1	SYSMEX CBC	2 LYMPHOCYTE	25	XS SERIES	137	28.145	2.019	7.17	21.100	35.200	
2026131X	1	SYSMEX CBC	3 MONOCYTE	25	XS SERIES	137	1.275	0.423	33.21	0	3.300	
2026131X	1	SYSMEX CBC	4 EOSINOPHIL	25	XS SERIES	137	13.232	0.647	4.89	9.900	16.500	
2026131X	1	SYSMEX CBC	5 BASOPHIL	25	XS SERIES	137	7.666	0.646	8.43	5.700	9.700	
2026131X	2	ACT PENTRA	1 NEUTROPHIL	15	COUL ACT 5	33	75.447	1.059	1.40	56.600	94.300	
2026131X	2	ACT PENTRA	1 NEUTROPHIL	24	ABX PENTRA	33	72.448	0.906	1.25	54.300	90.600	
2026131X	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	33	19.019	0.869	4.57	14.300	23.800	
2026131X	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	33	17.967	0.863	4.80	13.500	22.500	
2026131X	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	33	1.197	0.282	23.58	0	3.200	
2026131X	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	33	1.264	0.259	20.51	0	3.300	
2026131X	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	33	4.327	0.687	15.87	2.300	6.300	
2026131X	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	33	4.291	0.505	11.78	2.300	6.300	
2026131X	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	33	81.697	0.967	1.18	61.300	102.100	
2026131X	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	33	4.030	0.058	1.43	2.000	6.000	
2026131X	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	14	73.636	0.486	0.66	55.200	92.000	
2026131X	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	14	15.036	0.453	3.01	11.300	18.800	
2026131X	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	14	8.657	0.390	4.51	6.500	10.800	
2026131X	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	14	0.614	0.130	21.19	0	2.600	
2026131X	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	14	0.336	0.097	28.94	0	2.300	
2026131X	3	ADVIA 120	6 LUC	9	ADVIA-120	14	1.893	0.183	9.67	0	3.900	
2026131X	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	37	66.342	0.579	0.87	49.800	82.900	
2026131X	4	AB- CELL-D	1 NEUTROPHIL	34	EMERALD 22	16	59.400	2.639	4.44	44.600	74.300	
2026131X	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	40	65.962	0.664	1.01	49.500	82.500	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2026131X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	37	19.961	0.842	4.22	15.000	25.000			
2026131X	4 AB- CELL-D	2 LYMPHOCYTE	34 EMERALD 22	16	14.250	5.039	35.36	10.700	17.800			
2026131X	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	40	21.008	0.811	3.86	15.800	26.300			
2026131X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	37	6.403	0.444	6.93	4.400	8.400			
2026131X	4 AB- CELL-D	3 MONOCYTE	34 EMERALD 22	16	17.267	1.550	8.98	13.000	21.600			
2026131X	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	40	6.275	0.354	5.64	4.300	8.300			
2026131X	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	37	6.392	0.256	4.01	4.400	8.400			
2026131X	4 AB- CELL-D	4 EOSINOPHIL	34 EMERALD 22	16	7.244	2.498	34.49	5.200	9.200			
2026131X	4 AB- CELL-D	4 EOSINOPHIL	37 ABB.CEL RU	40	6.373	0.291	4.56	4.400	8.400			
2026131X	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	37	0.881	0.352	40.00	0	2.900			
2026131X	4 AB- CELL-D	5 BASOPHIL	34 EMERALD 22	16	0.393	0.246	62.60	0	2.400			
2026131X	4 AB- CELL-D	5 BASOPHIL	37 ABB.CEL RU	40	0.346	0.225	65.04	0	2.300			
2026131X	5 BECTON D	1 NEUTROPHIL	29 B.C600,800	49	60.796	0.984	1.62	45.600	76.000			
2026131X	5 BECTON D	2 LYMPHOCYTE	29 B.C600,800	49	28.261	1.191	4.22	21.200	35.300			
2026131X	5 BECTON D	3 MONOCYTE	29 B.C600,800	49	4.863	0.697	14.33	2.900	6.900			
2026131X	5 BECTON D	4 EOSINOPHIL	29 B.C600,800	49	6.067	0.324	5.34	4.100	8.100			
2026131X	5 BECTON D	5 BASOPHIL	29 B.C600,800	49	0.012	0.033	267.71	0	2.000			
2026131X	6 MR Mindray	1 NEUTROPHIL	32 BC-5390	71	52.817	0.882	1.67	39.600	66.000			
2026131X	6 MR Mindray	2 LYMPHOCYTE	32 BC-5390	71	30.673	1.767	5.76	23.000	38.300			
2026131X	6 MR Mindray	3 MONOCYTE	32 BC-5390	71	8.363	1.343	16.06	6.300	10.500			
2026131X	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	71	8.244	0.355	4.30	6.200	10.300			
2026131X	6 MR Mindray	5 BASOPHIL	32 BC-5390	71	28.128	0.279	0.99	21.100	35.200			
2026131X	7 DXH	1 NEUTROPHIL	36 BC DXH 500	109	80.540	1.075	1.33	60.400	100.700			
2026131X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	109	10.523	1.270	12.07	7.900	13.200			
2026131X	7 DXH	3 MONOCYTE	36 BC DXH 500	109	0.333	0.193	57.86	0	2.300			
2026131X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	109	8.524	0.693	8.13	6.400	10.700			
2026131X	7 DXH	5 BASOPHIL	36 BC DXH 500	109	0.097	0.196	203.22	0	2.100			
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2026132X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	136	60.858	2.419	3.97	45.600	76.100			
2026132X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	137	13.635	2.837	20.80	10.200	17.000			
2026132X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	137	0.402	0.312	77.63	0	2.400			

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026132X	1	SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	137	16.062	0.659	4.10	12.000	20.100	
2026132X	1	SYSMEX CBC	5 BASOPHIL	25 XS SERIES	137	9.117	0.794	8.71	6.800	11.400	
2026132X	2	ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	33	55.848	1.551	2.78	41.900	69.800	
2026132X	2	ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	33	54.333	0.894	1.65	40.800	67.900	
2026132X	2	ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	33	39.291	1.341	3.41	29.500	49.100	
2026132X	2	ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	33	37.945	0.954	2.51	28.500	47.400	
2026132X	2	ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	33	1.391	0.356	25.61	0	3.400	
2026132X	2	ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	33	1.184	0.227	19.13	0	3.200	
2026132X	2	ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	33	3.488	0.429	12.30	1.500	5.500	
2026132X	2	ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	33	3.536	0.315	8.91	1.500	5.500	
2026132X	2	ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	33	60.645	1.165	1.92	45.500	75.800	
2026132X	2	ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	33	2.988	0.033	1.11	1.000	5.000	
2026132X	3	ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	14	64.964	0.635	0.98	48.700	81.200	
2026132X	3	ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	14	24.271	0.661	2.72	18.200	30.300	
2026132X	3	ADVIA 120	3 MONOCYTE	9 ADVIA-120	14	6.979	0.438	6.27	5.000	9.000	
2026132X	3	ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	14	0.986	0.173	17.51	0	3.000	
2026132X	3	ADVIA 120	5 BASOPHIL	9 ADVIA-120	14	0.614	0.220	35.80	0	2.600	
2026132X	3	ADVIA 120	6 LUC	9 ADVIA-120	14	2.521	0.298	11.82	0.500	4.500	
2026132X	4	AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	37	52.986	0.958	1.81	39.700	66.200	
2026132X	4	AB- CELL-D	1 NEUTROPHIL	34 EMERALD 22	16	47.507	1.515	3.19	35.600	59.400	
2026132X	4	AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	40	51.558	1.409	2.73	38.700	64.400	
2026132X	4	AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	37	34.341	1.099	3.20	25.800	42.900	
2026132X	4	AB- CELL-D	2 LYMPHOCYTE	34 EMERALD 22	16	29.660	4.029	13.58	22.200	37.100	
2026132X	4	AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	40	36.198	1.821	5.03	27.100	45.200	
2026132X	4	AB- CELL-D	3 MONOCYTE	8 CELL-DYN	37	6.328	0.679	10.73	4.300	8.300	
2026132X	4	AB- CELL-D	3 MONOCYTE	34 EMERALD 22	16	17.140	2.723	15.89	12.900	21.400	
2026132X	4	AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	40	6.455	0.757	11.73	4.500	8.500	
2026132X	4	AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	37	5.327	0.436	8.18	3.300	7.300	
2026132X	4	AB- CELL-D	4 EOSINOPHIL	34 EMERALD 22	15	5.107	1.723	33.74	3.100	7.100	
2026132X	4	AB- CELL-D	4 EOSINOPHIL	37 ABB.CEL RU	40	5.248	0.416	7.93	3.200	7.200	
2026132X	4	AB- CELL-D	5 BASOPHIL	8 CELL-DYN	37	1.084	0.506	46.68	0	3.100	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026132X	4	AB- CELL-D	5	BASOPHIL	34	EMERALD 22	16	0.256	0.218	85.02	0	2.300
2026132X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	39	0.537	0.211	39.26	0	2.500
2026132X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	49	54.173	1.117	2.06	40.600	67.700
2026132X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	49	32.510	1.860	5.72	24.400	40.600
2026132X	5	BECTON D	3	MONOCYTE	29	B.C600,800	49	6.022	0.966	16.05	4.000	8.000
2026132X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	49	7.292	0.329	4.52	5.300	9.300
2026132X	5	BECTON D	5	BASOPHIL	29	B.C600,800	49	0.000	0.000	0.00	0	2.000
2026132X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	71	48.373	1.071	2.21	36.300	60.500
2026132X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	71	38.349	1.411	3.68	28.800	47.900
2026132X	6	MR Mindray	3	MONOCYTE	32	BC-5390	71	7.441	1.025	13.77	5.400	9.400
2026132X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	71	5.800	0.596	10.27	3.800	7.800
2026132X	6	MR Mindray	5	BASOPHIL	32	BC-5390	71	27.831	0.482	1.73	20.900	34.800
2026132X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	109	71.434	1.686	2.36	53.600	89.300
2026132X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	109	23.780	1.592	6.69	17.800	29.700
2026132X	7	DXH	3	MONOCYTE	36	BC DXH 500	109	0.551	0.398	72.28	0	2.600
2026132X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	109	3.933	0.914	23.23	1.900	5.900
2026132X	7	DXH	5	BASOPHIL	36	BC DXH 500	109	0.267	0.424	158.82	0	2.300
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 770			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2026133X	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	137	60.904	2.514	4.13	45.700	76.100
2026133X	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	137	13.167	2.975	22.59	9.900	16.500
2026133X	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	137	0.431	0.330	76.65	0	2.400
2026133X	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	137	16.153	0.630	3.90	12.100	20.200
2026133X	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	137	9.311	0.865	9.29	7.000	11.600
2026133X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	33	75.466	1.128	1.49	56.600	94.300
2026133X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	33	72.409	1.062	1.47	54.300	90.500
2026133X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	33	18.891	0.885	4.69	14.200	23.600
2026133X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	33	17.900	0.775	4.33	13.400	22.400
2026133X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	33	1.350	0.387	28.69	0	3.400
2026133X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	33	1.252	0.275	22.00	0	3.300
2026133X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	33	4.225	0.532	12.59	2.200	6.200
2026133X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	33	4.350	0.504	11.59	2.400	6.400

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026133X	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	33	81.555	1.067	1.31	61.200	101.900
2026133X	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	33	4.030	0.052	1.29	2.000	6.000
2026133X	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	14	73.621	0.665	0.90	55.200	92.000
2026133X	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	14	15.007	0.191	1.27	11.300	18.800
2026133X	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	14	8.643	0.507	5.86	6.500	10.800
2026133X	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	14	0.643	0.124	19.25	0	2.600
2026133X	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	14	0.293	0.088	30.17	0	2.300
2026133X	3	ADVIA 120	6 LUC	9	ADVIA-120	14	1.936	0.191	9.88	0	3.900
2026133X	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	37	52.881	0.825	1.56	39.700	66.100
2026133X	4	AB- CELL-D	1 NEUTROPHIL	34	EMERALD 22	16	47.807	1.599	3.35	35.900	59.800
2026133X	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	40	51.603	1.082	2.10	38.700	64.500
2026133X	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	37	34.432	1.622	4.71	25.800	43.000
2026133X	4	AB- CELL-D	2 LYMPHOCYTE	34	EMERALD 22	16	29.187	3.503	12.00	21.900	36.500
2026133X	4	AB- CELL-D	2 LYMPHOCYTE	37	ABB.CEL RU	40	35.810	1.558	4.35	26.900	44.800
2026133X	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	37	6.394	0.717	11.21	4.400	8.400
2026133X	4	AB- CELL-D	3 MONOCYTE	34	EMERALD 22	16	17.340	2.761	15.92	13.000	21.700
2026133X	4	AB- CELL-D	3 MONOCYTE	37	ABB.CEL RU	40	6.877	0.975	14.18	4.900	8.900
2026133X	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	37	5.419	0.392	7.24	3.400	7.400
2026133X	4	AB- CELL-D	4 EOSINOPHIL	34	EMERALD 22	16	5.320	0.838	15.74	3.300	7.300
2026133X	4	AB- CELL-D	4 EOSINOPHIL	37	ABB.CEL RU	40	5.168	0.377	7.30	3.200	7.200
2026133X	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	37	1.078	0.450	41.70	0	3.100
2026133X	4	AB- CELL-D	5 BASOPHIL	34	EMERALD 22	16	0.325	0.249	76.54	0	2.300
2026133X	4	AB- CELL-D	5 BASOPHIL	37	ABB.CEL RU	40	0.610	0.299	49.06	0	2.600
2026133X	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	49	53.710	0.853	1.59	40.300	67.100
2026133X	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	49	34.043	1.536	4.51	25.500	42.600
2026133X	5	BECTON D	3 MONOCYTE	29	B.C600,800	49	5.100	0.827	16.22	3.100	7.100
2026133X	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	49	7.212	0.340	4.71	5.200	9.200
2026133X	5	BECTON D	5 BASOPHIL	29	B.C600,800	49	0.000	0.000	0.00	0	2.000
2026133X	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	70	48.397	1.190	2.46	36.300	60.500
2026133X	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	71	38.043	1.243	3.27	28.500	47.600
2026133X	6	MR Mindray	3 MONOCYTE	32	BC-5390	72	7.652	1.078	14.09	5.700	9.700

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026133X	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	71	5.865	0.520	8.87	3.900	7.900		
2026133X	6 MR Mindray	5 BASOPHIL	32 BC-5390	71	27.842	0.401	1.44	20.900	34.800		
2026133X	7 DXH	1 NEUTROPHIL	36 BC DXH 500	109	80.669	1.177	1.46	60.500	100.800		
2026133X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	109	10.291	1.216	11.82	7.700	12.900		
2026133X	7 DXH	3 MONOCYTE	36 BC DXH 500	109	0.300	0.188	62.65	0	2.300		
2026133X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	109	8.755	0.696	7.96	6.600	10.900		
2026133X	7 DXH	5 BASOPHIL	36 BC DXH 500	109	0.037	0.047	125.63	0	2.000		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2026134X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	137	54.466	1.714	3.15	40.800	68.100		
2026134X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	137	21.478	1.530	7.12	16.100	26.800		
2026134X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	137	1.165	0.448	38.41	0	3.200		
2026134X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	136	14.208	0.693	4.87	10.700	17.800		
2026134X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	137	8.802	0.810	9.21	6.600	11.000		
2026134X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	33	55.864	1.352	2.42	41.900	69.800		
2026134X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	33	54.103	0.900	1.66	40.600	67.600		
2026134X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	33	39.215	1.305	3.33	29.400	49.000		
2026134X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	33	38.055	0.995	2.61	28.500	47.600		
2026134X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	33	1.350	0.322	23.86	0	3.400		
2026134X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	33	1.245	0.255	20.46	0	3.200		
2026134X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	33	3.485	0.457	13.12	1.500	5.500		
2026134X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	33	3.600	0.295	8.21	1.600	5.600		
2026134X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	33	60.324	1.262	2.09	45.200	75.400		
2026134X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	33	3.003	0.017	0.58	1.000	5.000		
2026134X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	14	64.454	1.037	1.61	48.300	80.600		
2026134X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	14	24.308	0.784	3.23	18.200	30.400		
2026134X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	14	7.164	0.709	9.89	5.200	9.200		
2026134X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	14	0.886	0.168	19.02	0	2.900		
2026134X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	14	0.600	0.181	30.21	0	2.600		
2026134X	3 ADVIA 120	6 LUC	9 ADVIA-120	14	2.657	0.638	24.00	0.700	4.700		
2026134X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	37	75.492	0.502	0.67	56.600	94.400		
2026134X	4 AB- CELL-D	1 NEUTROPHIL	34 EMERALD 22	16	73.553	0.960	1.31	55.200	91.900		

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026134X	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	39	75.226	0.604	0.80	56.400	94.000			
2026134X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	37	11.259	0.773	6.86	8.400	14.100			
2026134X	4 AB- CELL-D	2 LYMPHOCYTE	34 EMERALD 22	16	9.813	1.584	16.14	7.400	12.300			
2026134X	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	38	11.739	0.532	4.53	8.800	14.700			
2026134X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	37	3.530	0.451	12.77	1.500	5.500			
2026134X	4 AB- CELL-D	3 MONOCYTE	34 EMERALD 22	16	9.187	0.810	8.82	6.900	11.500			
2026134X	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	39	3.550	0.269	7.58	1.600	5.600			
2026134X	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	37	8.700	0.231	2.65	6.500	10.900			
2026134X	4 AB- CELL-D	4 EOSINOPHIL	34 EMERALD 22	16	7.167	0.994	13.88	5.200	9.200			
2026134X	4 AB- CELL-D	4 EOSINOPHIL	37 ABB.CEL RU	39	8.641	0.285	3.30	6.500	10.800			
2026134X	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	37	1.035	0.299	28.87	0	3.000			
2026134X	4 AB- CELL-D	5 BASOPHIL	34 EMERALD 22	16	0.263	0.176	67.17	0	2.300			
2026134X	4 AB- CELL-D	5 BASOPHIL	37 ABB.CEL RU	39	0.866	0.166	19.16	0	2.900			
2026134X	5 BECTON D	1 NEUTROPHIL	29 B.C600,800	49	66.808	0.566	0.85	50.100	83.500			
2026134X	5 BECTON D	2 LYMPHOCYTE	29 B.C600,800	49	23.588	0.675	2.86	17.700	29.500			
2026134X	5 BECTON D	3 MONOCYTE	29 B.C600,800	49	5.198	0.443	8.52	3.200	7.200			
2026134X	5 BECTON D	4 EOSINOPHIL	29 B.C600,800	49	4.446	0.205	4.61	2.400	6.400			
2026134X	5 BECTON D	5 BASOPHIL	29 B.C600,800	49	0.000	0.000	0.00	0	2.000			
2026134X	6 MR Mindray	1 NEUTROPHIL	32 BC-5390	71	62.334	0.663	1.06	46.800	77.900			
2026134X	6 MR Mindray	2 LYMPHOCYTE	32 BC-5390	71	20.699	1.023	4.94	15.500	25.900			
2026134X	6 MR Mindray	3 MONOCYTE	32 BC-5390	71	6.277	0.752	11.98	4.300	8.300			
2026134X	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	71	10.649	0.465	4.37	8.000	13.300			
2026134X	6 MR Mindray	5 BASOPHIL	32 BC-5390	71	31.323	0.157	0.50	23.500	39.200			
2026134X	7 DXH	1 NEUTROPHIL	36 BC DXH 500	108	71.001	1.828	2.57	53.300	88.800			
2026134X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	109	24.172	1.551	6.42	18.100	30.200			
2026134X	7 DXH	3 MONOCYTE	36 BC DXH 500	109	0.468	0.341	72.90	0	2.500			
2026134X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	109	4.091	0.930	22.74	2.100	6.100			
2026134X	7 DXH	5 BASOPHIL	36 BC DXH 500	110	0.251	0.406	161.66	0	2.300			
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 770	EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2026135X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	137	49.908	1.721	3.45	37.400	62.400			
2026135X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	137	27.918	2.137	7.66	20.900	34.900			

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026135X	1	SYSMEX CBC	3 MONOCYTE	25	XS SERIES	137	1.278	0.426	33.29	0	3.300
2026135X	1	SYSMEX CBC	4 EOSINOPHIL	25	XS SERIES	137	13.299	0.695	5.23	10.000	16.600
2026135X	1	SYSMEX CBC	5 BASOPHIL	25	XS SERIES	137	7.602	0.665	8.75	5.600	9.600
2026135X	2	ACT PENTRA	1 NEUTROPHIL	15	COUL ACT 5	33	51.815	2.715	5.24	38.900	64.800
2026135X	2	ACT PENTRA	1 NEUTROPHIL	24	ABX PENTRA	33	51.003	1.737	3.41	38.300	63.800
2026135X	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	33	39.903	2.428	6.09	29.900	49.900
2026135X	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	33	38.091	1.613	4.24	28.600	47.600
2026135X	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	33	1.121	0.366	32.62	0	3.100
2026135X	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	33	1.016	0.360	35.42	0	3.000
2026135X	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	33	6.819	0.996	14.61	4.800	8.800
2026135X	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	33	7.055	0.668	9.47	5.100	9.100
2026135X	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	33	56.691	1.086	1.92	42.500	70.900
2026135X	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	33	2.822	0.065	2.30	0.800	4.800
2026135X	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	14	47.850	1.722	3.60	35.900	59.800
2026135X	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	14	33.600	1.110	3.30	25.200	42.000
2026135X	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	14	13.036	1.375	10.55	9.800	16.300
2026135X	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	14	0.736	0.187	25.48	0	2.700
2026135X	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	14	0.786	0.329	41.90	0	2.800
2026135X	3	ADVIA 120	6 LUC	9	ADVIA-120	14	3.871	0.831	21.47	1.900	5.900
2026135X	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	37	66.542	0.617	0.93	49.900	83.200
2026135X	4	AB- CELL-D	1 NEUTROPHIL	34	EMERALD 22	16	59.473	3.026	5.09	44.600	74.300
2026135X	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	38	66.139	0.705	1.07	49.600	82.700
2026135X	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	37	19.653	1.012	5.15	14.700	24.600
2026135X	4	AB- CELL-D	2 LYMPHOCYTE	34	EMERALD 22	16	14.281	5.429	38.01	10.700	17.900
2026135X	4	AB- CELL-D	2 LYMPHOCYTE	37	ABB.CEL RU	38	20.974	0.918	4.38	15.700	26.200
2026135X	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	37	6.397	0.438	6.85	4.400	8.400
2026135X	4	AB- CELL-D	3 MONOCYTE	34	EMERALD 22	16	17.240	1.343	7.79	12.900	21.600
2026135X	4	AB- CELL-D	3 MONOCYTE	37	ABB.CEL RU	38	6.171	0.489	7.93	4.200	8.200
2026135X	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	37	6.462	0.309	4.78	4.500	8.500
2026135X	4	AB- CELL-D	4 EOSINOPHIL	34	EMERALD 22	16	7.194	2.719	37.79	5.200	9.200
2026135X	4	AB- CELL-D	4 EOSINOPHIL	37	ABB.CEL RU	39	6.443	0.359	5.57	4.400	8.400

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026135X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	37	0.868	0.373	42.97	0	2.900
2026135X	4	AB- CELL-D	5	BASOPHIL	34	EMERALD 22	16	0.450	0.285	63.34	0	2.500
2026135X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	39	0.348	0.205	58.89	0	2.300
2026135X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	49	60.508	1.058	1.75	45.400	75.600
2026135X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	49	28.878	1.168	4.04	21.700	36.100
2026135X	5	BECTON D	3	MONOCYTE	29	B.C600,800	49	4.598	0.636	13.82	2.600	6.600
2026135X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	49	6.000	0.263	4.38	4.000	8.000
2026135X	5	BECTON D	5	BASOPHIL	29	B.C600,800	49	0.016	0.037	226.38	0	2.000
2026135X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	71	52.636	0.926	1.76	39.500	65.800
2026135X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	71	30.761	1.504	4.89	23.100	38.500
2026135X	6	MR Mindray	3	MONOCYTE	32	BC-5390	71	8.341	1.114	13.35	6.300	10.400
2026135X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	71	8.194	0.412	5.03	6.100	10.200
2026135X	6	MR Mindray	5	BASOPHIL	32	BC-5390	71	28.117	0.238	0.85	21.100	35.100
2026135X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	109	50.318	4.777	9.49	37.700	62.900
2026135X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	108	35.573	4.945	13.90	26.700	44.500
2026135X	7	DXH	3	MONOCYTE	36	BC DXH 500	109	0.509	0.204	40.00	0	2.500
2026135X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	109	13.631	1.542	11.31	10.200	17.000
2026135X	7	DXH	5	BASOPHIL	36	BC DXH 500	109	0.084	0.066	78.53	0	2.100

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
185 Diff 6 Parameter Ins			CLIA TEST ID #: 770			EVALUATION CRITERIA: TARGET VALUE			25 % OR 2.00 {GREATER}			
2026131Y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	62	52.257	0.825	1.58	39.200	65.300
2026131Y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	258	49.728	1.492	3.00	37.300	62.200

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2026131Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	62	26.248	0.836	3.19	19.700	32.800			
2026131Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	258	28.052	1.077	3.84	21.000	35.100			
2026131Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	62	2.603	0.475	18.24	0.600	4.600			
2026131Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	258	1.413	0.363	25.70	0	3.400			
2026131Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	62	13.885	0.276	1.99	10.400	17.400			
2026131Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	258	13.614	0.479	3.52	10.200	17.000			
2026131Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	62	4.919	0.226	4.59	2.900	6.900			
2026131Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	258	7.390	0.554	7.49	5.400	9.400			
2026131Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	61	12.580	0.211	1.67	9.400	15.700			
2026131Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	256	12.936	0.428	3.31	9.700	16.200			
2026131Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	25	0.016	0.037	222.79	0	2.000			
185 Diff 6 Parameter Ins		CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2026132Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	62	62.626	1.258	2.01	47.000	78.300			
2026132Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	258	61.045	1.752	2.87	45.800	76.300			
2026132Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	62	14.679	1.448	9.87	11.000	18.300			
2026132Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	258	13.029	1.194	9.17	9.800	16.300			
2026132Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	63	1.026	0.431	42.05	0	3.000			
2026132Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	257	0.595	0.315	52.93	0	2.600			
2026132Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	62	16.525	0.361	2.18	12.400	20.700			
2026132Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	258	16.461	0.596	3.62	12.300	20.600			
2026132Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	62	4.905	0.088	1.79	2.900	6.900			
2026132Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	258	9.020	0.697	7.73	6.800	11.300			
2026132Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	61	14.892	0.477	3.20	11.200	18.600			
2026132Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	256	16.013	0.541	3.38	12.000	20.000			
2026132Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	25	0.088	0.139	157.52	0	2.100			
2026133Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	62	62.812	1.105	1.76	47.100	78.500			
2026133Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	258	61.036	1.787	2.93	45.800	76.300			
2026133Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	62	14.397	1.619	11.25	10.800	18.000			
2026133Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	258	13.071	1.242	9.50	9.800	16.300			

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026133Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	63	1.046	0.507	48.46	0	3.000		
2026133Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	257	0.566	0.266	47.03	0	2.600		
2026133Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	62	16.570	0.399	2.41	12.400	20.700		
2026133Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	258	16.420	0.608	3.71	12.300	20.500		
2026133Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	62	4.911	0.109	2.21	2.900	6.900		
2026133Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	258	9.024	0.692	7.67	6.800	11.300		
2026133Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	61	14.842	0.389	2.62	11.100	18.600		
2026133Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	256	15.916	0.559	3.52	11.900	19.900		
2026133Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	25	0.092	0.160	173.70	0	2.100		
185 Diff 6 Parameter Ins		CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2026134Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	62	58.310	1.012	1.74	43.700	72.900		
2026134Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	258	55.270	1.383	2.50	41.500	69.100		
2026134Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	62	19.884	0.702	3.53	14.900	24.900		
2026134Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	258	20.908	1.169	5.59	15.700	26.100		
2026134Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	62	1.882	0.336	17.83	0	3.900		
2026134Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	258	1.053	0.202	19.16	0	3.100		
2026134Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	62	14.887	0.484	3.25	11.200	18.600		
2026134Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	258	14.763	0.547	3.71	11.100	18.500		
2026134Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	62	4.934	0.396	8.02	2.900	6.900		
2026134Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	258	8.191	0.574	7.01	6.100	10.200		
2026134Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	61	14.432	0.435	3.02	10.800	18.000		
2026134Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	256	14.688	0.593	4.04	11.000	18.400		
2026134Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	24	0.004	0.020	469.04	0	2.000		
2026135Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	62	52.290	0.659	1.26	39.200	65.400		
2026135Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	258	49.841	1.752	3.52	37.400	62.300		
2026135Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	62	26.325	0.909	3.45	19.700	32.900		
2026135Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	258	27.869	1.282	4.60	20.900	34.800		
2026135Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	62	2.582	0.491	19.02	0.600	4.600		
2026135Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	258	1.427	0.366	25.65	0	3.400		

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026135Y	1	6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	63	13.868	0.247	1.78	10.400	17.300
2026135Y	1	6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	257	13.697	0.480	3.51	10.300	17.100
2026135Y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	62	4.974	0.365	7.33	3.000	7.000
2026135Y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	258	7.416	0.565	7.62	5.400	9.400
2026135Y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	61	12.581	0.201	1.60	9.400	15.700
2026135Y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	256	12.957	0.488	3.77	9.700	16.200
2026135Y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	25	0.020	0.040	195.33	0	2.000

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 770			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2026131Z	8	3ST	1	Lymphocyte	1	KX 21/X300	12	12.225	0.618	5.05	9.200	15.300
2026131Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	13	13.269	1.511	11.38	10.000	16.600
2026131Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	12	19.417	1.150	5.92	14.600	24.300
2026131Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	13	13.323	1.100	8.26	10.000	16.700
2026131Z	8	3ST	3	Neutrophil	1	KX 21/X300	12	68.358	1.280	1.87	51.300	85.400
2026131Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	13	73.408	1.706	2.32	55.100	91.800
2026132Z	8	3ST	1	Lymphocyte	1	KX 21/X300	12	61.525	0.673	1.09	46.100	76.900
2026132Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	13	60.592	1.065	1.76	45.400	75.700
2026132Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	12	12.550	0.514	4.10	9.400	15.700
2026132Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	13	9.485	0.532	5.61	7.100	11.900
2026132Z	8	3ST	3	Neutrophil	1	KX 21/X300	12	25.925	0.855	3.30	19.400	32.400
2026132Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	13	29.908	1.041	3.48	22.400	37.400
2026133Z	8	3ST	1	Lymphocyte	1	KX 21/X300	12	29.758	1.071	3.60	22.300	37.200
2026133Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	13	31.531	1.163	3.69	23.600	39.400
2026133Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	12	18.625	1.006	5.40	14.000	23.300

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 128 DIFF 3 PARAMETER INS									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2026133Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	13	12.462	0.692	5.56	9.300	15.600		
2026133Z	8 3ST	3	Neutrophil	1	KX 21/X300	12	51.617	1.066	2.07	38.700	64.500		
2026133Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	13	56.000	1.465	2.62	42.000	70.000		
186 DIFF 3 PARAMETER INS		CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2026134Z	8 3ST	1	Lymphocyte	1	KX 21/X300	12	11.983	0.841	7.02	9.000	15.000		
2026134Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	13	13.377	1.243	9.29	10.000	16.700		
2026134Z	8 3ST	2	Mix M/E/Ba	1	KX 21/X300	12	19.333	1.211	6.26	14.500	24.200		
2026134Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	13	13.438	1.574	11.71	10.100	16.800		
2026134Z	8 3ST	3	Neutrophil	1	KX 21/X300	11	68.718	1.615	2.35	51.500	85.900		
2026134Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	13	73.185	2.120	2.90	54.900	91.500		
2026135Z	8 3ST	1	Lymphocyte	1	KX 21/X300	12	61.467	0.833	1.36	46.100	76.800		
2026135Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	13	60.942	0.512	0.84	45.700	76.200		
2026135Z	8 3ST	2	Mix M/E/Ba	1	KX 21/X300	12	12.550	0.701	5.58	9.400	15.700		
2026135Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	13	9.308	0.617	6.63	7.000	11.600		
2026135Z	8 3ST	3	Neutrophil	1	KX 21/X300	12	25.983	0.824	3.17	19.500	32.500		
2026135Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	13	30.015	0.815	2.72	22.500	37.500		

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
549 RED CELL COUNT (RBC)		CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 4 %									
2026-131	1 Sysmex CBC	132	SYSMEX XS	135	4.571	0.058	1.27	4.390	4.750				
2026-131	1 Sysmex CBC	141	SYSMEX XN	64	4.587	0.049	1.07	4.400	4.770				
2026-131	1 Sysmex CBC	152	Sysmex XN	257	4.549	0.049	1.09	4.370	4.730				
2026-131	2 ACT PENTRA	125	COULTER AC	32	5.115	0.093	1.81	4.910	5.320				
2026-131	2 ACT PENTRA	130	ABX PENTRA	33	5.129	0.073	1.42	4.920	5.330				
2026-131	3 ADVIA 120	116	ADVIA-120	14	5.142	0.092	1.79	4.940	5.350				

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-131	4	AB-CELL DY	115 ABBOTT C-D	30	4.757	0.093	1.95	4.570	4.950	
2026-131	4	AB-CELL DY	142 EMERALD	17	4.656	0.118	2.54	4.470	4.840	
2026-131	4	AB-CELL DY	153 AB-CEL-RUB	50	4.872	0.091	1.87	4.680	5.070	
2026-131	5	BECTON D	137 B.C DXH	49	4.074	0.060	1.47	3.910	4.240	
2026-131	6	MR Mindray	145 BC-5390	71	4.597	0.083	1.81	4.410	4.780	
2026-131	7	DXH500 Ser	149 BC DXH 500	109	5.235	0.097	1.85	5.030	5.440	
2026-131	8	3 ST	84 ABBOTT C-D	14	2.453	0.071	2.91	2.360	2.550	
549	RED CELL COUNT (RBC)		CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 4 %						
2026-132	1	Sysmex CBC	132 SYSMEX XS	135	2.219	0.028	1.28	2.130	2.310	
2026-132	1	Sysmex CBC	141 SYSMEX XN	64	2.206	0.026	1.20	2.120	2.290	
2026-132	1	Sysmex CBC	152 Sysmex XN	257	2.175	0.026	1.19	2.090	2.260	
2026-132	2	ACT PENTRA	125 COULTER AC	32	4.601	0.056	1.21	4.420	4.780	
2026-132	2	ACT PENTRA	130 ABX PENTRA	33	4.624	0.057	1.22	4.440	4.810	
2026-132	3	ADVIA 120	116 ADVIA-120	14	4.454	0.067	1.50	4.280	4.630	
2026-132	4	AB-CELL DY	115 ABBOTT C-D	30	2.219	0.046	2.07	2.130	2.310	
2026-132	4	AB-CELL DY	142 EMERALD	17	2.122	0.059	2.76	2.040	2.210	
2026-132	4	AB-CELL DY	153 AB-CEL-RUB	50	2.226	0.045	2.04	2.140	2.320	
2026-132	5	BECTON D	137 B.C DXH	49	2.473	0.035	1.41	2.370	2.570	
2026-132	6	MR Mindray	145 BC-5390	71	2.271	0.041	1.81	2.180	2.360	
2026-132	7	DXH500 Ser	149 BC DXH 500	109	4.512	0.068	1.50	4.330	4.690	
2026-132	8	3 ST	84 ABBOTT C-D	14	5.902	0.087	1.48	5.670	6.140	
2026-133	1	Sysmex CBC	132 SYSMEX XS	135	2.218	0.029	1.32	2.130	2.310	
2026-133	1	Sysmex CBC	141 SYSMEX XN	64	2.205	0.029	1.30	2.120	2.290	
2026-133	1	Sysmex CBC	152 Sysmex XN	257	2.169	0.024	1.12	2.080	2.260	
2026-133	2	ACT PENTRA	125 COULTER AC	32	5.100	0.054	1.07	4.900	5.300	
2026-133	2	ACT PENTRA	130 ABX PENTRA	33	5.120	0.067	1.31	4.920	5.320	
2026-133	3	ADVIA 120	116 ADVIA-120	14	5.155	0.114	2.22	4.950	5.360	
2026-133	4	AB-CELL DY	115 ABBOTT C-D	30	2.211	0.045	2.06	2.120	2.300	
2026-133	4	AB-CELL DY	142 EMERALD	17	2.126	0.062	2.91	2.040	2.210	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026-133	4 AB-CELL DY	153 AB-CEL-RUB		50	2.217	0.054	2.44	2.130	2.310		
2026-133	5 BECTON D	137 B.C DXH		49	2.468	0.037	1.48	2.370	2.570		
2026-133	6 MR Mindray	145 BC-5390		71	2.272	0.042	1.87	2.180	2.360		
2026-133	7 DXH500 Ser	149 BC DXH 500		109	5.208	0.074	1.42	5.000	5.420		
2026-133	8 3 ST	84 ABBOTT C-D		14	4.151	0.084	2.02	3.980	4.320		
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 4 %								
2026-134	1 Sysmex CBC	132 SYSMEX XS		135	5.714	0.073	1.28	5.490	5.940		
2026-134	1 Sysmex CBC	141 SYSMEX XN		64	5.747	0.047	0.81	5.520	5.980		
2026-134	1 Sysmex CBC	152 Sysmex XN		257	5.718	0.054	0.95	5.490	5.950		
2026-134	2 ACT PENTRA	125 COULTER AC		32	4.617	0.049	1.06	4.430	4.800		
2026-134	2 ACT PENTRA	130 ABX PENTRA		33	4.635	0.058	1.24	4.450	4.820		
2026-134	3 ADVIA 120	116 ADVIA-120		14	4.465	0.066	1.48	4.290	4.640		
2026-134	4 AB-CELL DY	115 ABBOTT C-D		30	5.108	0.074	1.46	4.900	5.310		
2026-134	4 AB-CELL DY	142 EMERALD		17	5.024	0.100	1.99	4.820	5.220		
2026-134	4 AB-CELL DY	153 AB-CEL-RUB		50	5.293	0.109	2.06	5.080	5.500		
2026-134	5 BECTON D	137 B.C DXH		49	5.366	0.080	1.49	5.150	5.580		
2026-134	6 MR Mindray	145 BC-5390		71	5.373	0.106	1.97	5.160	5.590		
2026-134	7 DXH500 Ser	149 BC DXH 500		109	4.516	0.068	1.52	4.340	4.700		
2026-134	8 3 ST	84 ABBOTT C-D		14	2.457	0.079	3.21	2.360	2.560		
2026-135	1 Sysmex CBC	132 SYSMEX XS		135	4.572	0.058	1.26	4.390	4.750		
2026-135	1 Sysmex CBC	141 SYSMEX XN		64	4.590	0.044	0.96	4.410	4.770		
2026-135	1 Sysmex CBC	152 Sysmex XN		257	4.548	0.048	1.05	4.370	4.730		
2026-135	2 ACT PENTRA	125 COULTER AC		32	2.337	0.039	1.68	2.240	2.430		
2026-135	2 ACT PENTRA	130 ABX PENTRA		33	2.343	0.046	1.97	2.250	2.440		
2026-135	3 ADVIA 120	116 ADVIA-120		14	1.997	0.031	1.54	1.920	2.080		
2026-135	4 AB-CELL DY	115 ABBOTT C-D		30	4.728	0.089	1.88	4.540	4.920		
2026-135	4 AB-CELL DY	142 EMERALD		17	4.645	0.099	2.13	4.460	4.830		
2026-135	4 AB-CELL DY	153 AB-CEL-RUB		50	4.856	0.094	1.94	4.660	5.050		
2026-135	5 BECTON D	137 B.C DXH		49	4.072	0.052	1.27	3.910	4.240		

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-135	6 MR Mindray	145 BC-5390			71	4.604	0.073	1.59	4.420	4.790	
2026-135	7 DXH500 Ser	149 BC DXH 500			109	2.325	0.035	1.51	2.230	2.420	
2026-135	8 3 ST	84 ABBOTT C-D			14	5.882	0.157	2.67	5.650	6.120	
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 4 %							
2026-131	1 Sysmex CBC	132 SYSMEX XS			135	38.754	0.723	1.87	37.200	40.300	
2026-131	1 Sysmex CBC	141 SYSMEX XN			65	37.408	0.668	1.79	35.900	38.900	
2026-131	1 Sysmex CBC	152 Sysmex XN			256	37.424	0.709	1.89	35.900	38.900	
2026-131	2 ACT PENTRA	125 COULTER AC			32	46.853	0.965	2.06	45.000	48.700	
2026-131	2 ACT PENTRA	130 ABX PENTRA			33	46.838	0.902	1.93	45.000	48.700	
2026-131	3 ADVIA 120	116 ADVIA-120			14	45.429	1.221	2.69	43.600	47.200	
2026-131	4 AB-CELL DY	115 ABBOTT C-D			31	38.103	0.749	1.96	36.600	39.600	
2026-131	4 AB-CELL DY	142 EMERALD			17	40.241	1.103	2.74	38.600	41.900	
2026-131	4 AB-CELL DY	153 AB-CEL-RUB			49	39.008	0.955	2.45	37.400	40.600	
2026-131	5 BECTON D	137 B.C DXH			49	38.779	0.541	1.40	37.200	40.300	
2026-131	6 MR Mindray	145 BC-5390			71	38.946	0.934	2.40	37.400	40.500	
2026-131	7 DXH500 Ser	149 BC DXH 500			108	49.725	0.992	2.00	47.700	51.700	
2026-131	8 3 ST	84 ABBOTT C-D			14	18.123	0.790	4.36	17.400	18.800	
2026-132	1 Sysmex CBC	132 SYSMEX XS			135	17.944	0.352	1.96	17.200	18.700	
2026-132	1 Sysmex CBC	141 SYSMEX XN			65	16.997	0.310	1.83	16.300	17.700	
2026-132	1 Sysmex CBC	152 Sysmex XN			256	17.027	0.321	1.88	16.300	17.700	
2026-132	2 ACT PENTRA	125 COULTER AC			32	39.531	0.689	1.74	38.000	41.100	
2026-132	2 ACT PENTRA	130 ABX PENTRA			33	39.385	0.663	1.68	37.800	41.000	
2026-132	3 ADVIA 120	116 ADVIA-120			14	35.393	0.688	1.94	34.000	36.800	
2026-132	4 AB-CELL DY	115 ABBOTT C-D			31	15.841	0.352	2.22	15.200	16.500	
2026-132	4 AB-CELL DY	142 EMERALD			17	16.500	0.580	3.52	15.800	17.200	
2026-132	4 AB-CELL DY	153 AB-CEL-RUB			49	15.868	0.418	2.63	15.200	16.500	
2026-132	5 BECTON D	137 B.C DXH			49	19.965	0.326	1.63	19.200	20.800	
2026-132	6 MR Mindray	145 BC-5390			71	18.011	0.354	1.97	17.300	18.700	
2026-132	7 DXH500 Ser	149 BC DXH 500			108	39.485	0.705	1.79	37.900	41.100	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2026-132	8 3 ST	84	ABBOTT C-D	14	52.785	1.513	2.87	50.700	54.900		
550	HEMATOCRIT (HCT)	CLIA TEST ID #: 785	EVALUATION CRITERIA: TARGET VALUE 4 %								
2026-133	1 Sysmex CBC	132	SYSMEX XS	135	17.956	0.332	1.85	17.200	18.700		
2026-133	1 Sysmex CBC	141	SYSMEX XN	65	17.018	0.308	1.81	16.300	17.700		
2026-133	1 Sysmex CBC	152	Systemex XN	256	16.984	0.338	1.99	16.300	17.700		
2026-133	2 ACT PENTRA	125	COULTER AC	32	46.638	0.836	1.79	44.800	48.500		
2026-133	2 ACT PENTRA	130	ABX PENTRA	33	46.548	0.745	1.60	44.700	48.400		
2026-133	3 ADVIA 120	116	ADVIA-120	14	45.429	1.317	2.90	43.600	47.200		
2026-133	4 AB-CELL DY	115	ABBOTT C-D	31	15.793	0.423	2.68	15.200	16.400		
2026-133	4 AB-CELL DY	142	EMERALD	17	16.488	0.588	3.57	15.800	17.100		
2026-133	4 AB-CELL DY	153	AB-CEL-RUB	49	15.800	0.421	2.66	15.200	16.400		
2026-133	5 BECTON D	137	B.C DXH	49	19.924	0.333	1.67	19.100	20.700		
2026-133	6 MR Mindray	145	BC-5390	71	18.013	0.417	2.31	17.300	18.700		
2026-133	7 DXH500 Ser	149	BC DXH 500	108	49.496	0.839	1.69	47.500	51.500		
2026-133	8 3 ST	84	ABBOTT C-D	14	34.692	0.999	2.88	33.300	36.100		
2026-134	1 Sysmex CBC	132	SYSMEX XS	135	51.974	0.983	1.89	49.900	54.100		
2026-134	1 Sysmex CBC	141	SYSMEX XN	65	50.129	0.763	1.52	48.100	52.100		
2026-134	1 Sysmex CBC	152	Systemex XN	256	50.266	0.875	1.74	48.300	52.300		
2026-134	2 ACT PENTRA	125	COULTER AC	32	39.588	0.609	1.54	38.000	41.200		
2026-134	2 ACT PENTRA	130	ABX PENTRA	33	39.497	0.660	1.67	37.900	41.100		
2026-134	3 ADVIA 120	116	ADVIA-120	14	35.371	0.783	2.21	34.000	36.800		
2026-134	4 AB-CELL DY	115	ABBOTT C-D	31	43.163	0.772	1.79	41.400	44.900		
2026-134	4 AB-CELL DY	142	EMERALD	17	46.459	1.416	3.05	44.600	48.300		
2026-134	4 AB-CELL DY	153	AB-CEL-RUB	49	44.976	1.271	2.83	43.200	46.800		
2026-134	5 BECTON D	137	B.C DXH	49	56.788	0.732	1.29	54.500	59.100		
2026-134	6 MR Mindray	145	BC-5390	71	48.530	1.325	2.73	46.600	50.500		
2026-134	7 DXH500 Ser	149	BC DXH 500	108	39.463	0.715	1.81	37.900	41.000		
2026-134	8 3 ST	84	ABBOTT C-D	14	18.046	0.745	4.13	17.300	18.800		

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
550	HEMATOCRIT (HCT)	CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 4 %					
2026-135	1	Sysmex CBC	132 SYSMEX XS	135	38.714	0.707	1.83	37.200	40.300
2026-135	1	Sysmex CBC	141 SYSMEX XN	65	37.442	0.649	1.73	35.900	38.900
2026-135	1	Sysmex CBC	152 Sysmex XN	256	37.414	0.668	1.78	35.900	38.900
2026-135	2	ACT PENTRA	125 COULTER AC	32	18.628	0.450	2.42	17.900	19.400
2026-135	2	ACT PENTRA	130 ABX PENTRA	33	18.603	0.279	1.50	17.900	19.300
2026-135	3	ADVIA 120	116 ADVIA-120	14	15.086	0.285	1.89	14.500	15.700
2026-135	4	AB-CELL DY	115 ABBOTT C-D	31	37.955	0.690	1.82	36.400	39.500
2026-135	4	AB-CELL DY	142 EMERALD	17	39.653	0.998	2.52	38.100	41.200
2026-135	4	AB-CELL DY	153 AB-CEL-RUB	49	38.930	1.070	2.75	37.400	40.500
2026-135	5	BECTON D	137 B.C DXH	49	38.841	0.574	1.48	37.300	40.400
2026-135	6	MR Mindray	145 BC-5390	71	38.869	1.035	2.66	37.300	40.400
2026-135	7	DXH500 Ser	149 BC DXH 500	108	18.783	0.380	2.02	18.000	19.500
2026-135	8	3 ST	84 ABBOTT C-D	14	53.038	1.767	3.33	50.900	55.200
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795							
2026-131	1	Sysmex CBC	132 SYSMEX XS	137	13.064	0.153	1.17	12.500	13.600
2026-131	1	Sysmex CBC	141 SYSMEX XN	64	13.086	0.117	0.89	12.600	13.600
2026-131	1	Sysmex CBC	152 Sysmex XN	254	13.060	0.117	0.90	12.500	13.600
2026-131	2	ACT PENTRA	125 COULTER AC	32	16.288	0.210	1.29	15.600	16.900
2026-131	2	ACT PENTRA	130 ABX PENTRA	33	16.372	0.179	1.09	15.700	17.000
2026-131	3	ADVIA 120	116 ADVIA-120	14	16.836	0.241	1.43	16.200	17.500
2026-131	4	AB-CELL DY	115 ABBOTT C-D	31	13.847	0.223	1.61	13.300	14.400
2026-131	4	AB-CELL DY	142 EMERALD	17	11.900	0.180	1.51	11.400	12.400
2026-131	4	AB-CELL DY	153 AB-CEL-RUB	49	13.790	0.203	1.47	13.200	14.300
2026-131	5	BECTON D	137 B.C DXH	49	12.053	0.139	1.15	11.600	12.500
2026-131	6	MR Mindray	145 BC-5390	71	13.316	0.170	1.27	12.800	13.800
2026-131	7	DXH500 Ser	149 BC DXH 500	109	17.374	0.281	1.62	16.700	18.100
2026-131	8	3 ST	84 ABBOTT C-D	14	6.385	0.211	3.30	6.100	6.600
2026-131	8	3 ST	138 SY KX-21N	10	7.310	3.431	46.94	7.000	7.600

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795		EVALUATION CRITERIA: TARGET VALUE 4 %							
2026-132	1	Sysmex CBC	132	SYSMEX XS	137	5.914	0.099	1.67	5.700	6.200	
2026-132	1	Sysmex CBC	141	SYSMEX XN	64	5.951	0.073	1.23	5.700	6.200	
2026-132	1	Sysmex CBC	152	Sysmex XN	254	5.932	0.069	1.16	5.700	6.200	
2026-132	2	ACT PENTRA	125	COULTER AC	32	13.785	0.150	1.09	13.200	14.300	
2026-132	2	ACT PENTRA	130	ABX PENTRA	33	13.809	0.180	1.30	13.300	14.400	
2026-132	3	ADVIA 120	116	ADVIA-120	14	12.971	0.167	1.28	12.500	13.500	
2026-132	4	AB-CELL DY	115	ABBOTT C-D	31	5.910	0.089	1.51	5.700	6.100	
2026-132	4	AB-CELL DY	142	EMERALD	17	4.688	0.086	1.83	4.500	4.900	
2026-132	4	AB-CELL DY	153	AB-CEL-RUB	49	5.694	0.105	1.84	5.500	5.900	
2026-132	5	BECTON D	137	B.C DXH	49	6.245	0.065	1.03	6.000	6.500	
2026-132	6	MR Mindray	145	BC-5390	71	5.940	0.093	1.57	5.700	6.200	
2026-132	7	DXH500 Ser	149	BC DXH 500	109	13.634	0.157	1.15	13.100	14.200	
2026-132	8	3 ST	84	ABBOTT C-D	14	18.108	0.414	2.29	17.400	18.800	
2026-132	8	3 ST	138	SY KX-21N	10	17.650	1.371	7.77	16.900	18.400	
2026-133	1	Sysmex CBC	132	SYSMEX XS	137	5.902	0.104	1.75	5.700	6.100	
2026-133	1	Sysmex CBC	141	SYSMEX XN	64	5.950	0.071	1.19	5.700	6.200	
2026-133	1	Sysmex CBC	152	Sysmex XN	254	5.921	0.077	1.31	5.700	6.200	
2026-133	2	ACT PENTRA	125	COULTER AC	32	16.278	0.220	1.35	15.600	16.900	
2026-133	2	ACT PENTRA	130	ABX PENTRA	33	16.403	0.178	1.08	15.700	17.100	
2026-133	3	ADVIA 120	116	ADVIA-120	14	16.843	0.176	1.05	16.200	17.500	
2026-133	4	AB-CELL DY	115	ABBOTT C-D	31	5.913	0.094	1.59	5.700	6.100	
2026-133	4	AB-CELL DY	142	EMERALD	17	4.706	0.083	1.76	4.500	4.900	
2026-133	4	AB-CELL DY	153	AB-CEL-RUB	49	5.684	0.110	1.94	5.500	5.900	
2026-133	5	BECTON D	137	B.C DXH	49	6.245	0.070	1.12	6.000	6.500	
2026-133	6	MR Mindray	145	BC-5390	71	5.940	0.082	1.38	5.700	6.200	
2026-133	7	DXH500 Ser	149	BC DXH 500	109	17.244	0.213	1.24	16.600	17.900	
2026-133	8	3 ST	84	ABBOTT C-D	14	12.146	0.268	2.20	11.700	12.600	
2026-133	8	3 ST	138	SY KX-21N	10	12.420	1.631	13.13	11.900	12.900	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795		EVALUATION CRITERIA: TARGET VALUE 4 %							
2026-134	1	Sysmex CBC	132	SYSMEX XS	137	17.461	0.212	1.21	16.800	18.200	
2026-134	1	Sysmex CBC	141	SYSMEX XN	64	17.355	0.129	0.74	16.700	18.000	
2026-134	1	Sysmex CBC	152	Sysmex XN	254	17.347	0.140	0.81	16.700	18.000	
2026-134	2	ACT PENTRA	125	COULTER AC	32	13.801	0.161	1.17	13.200	14.400	
2026-134	2	ACT PENTRA	130	ABX PENTRA	33	13.806	0.172	1.25	13.300	14.400	
2026-134	3	ADVIA 120	116	ADVIA-120	14	12.971	0.167	1.28	12.500	13.500	
2026-134	4	AB-CELL DY	115	ABBOTT C-D	31	16.558	0.272	1.64	15.900	17.200	
2026-134	4	AB-CELL DY	142	EMERALD	17	14.981	0.170	1.14	14.400	15.600	
2026-134	4	AB-CELL DY	153	AB-CEL-RUB	49	16.582	0.262	1.58	15.900	17.200	
2026-134	5	BECTON D	137	B.C DXH	49	16.943	0.198	1.17	16.300	17.600	
2026-134	6	MR Mindray	145	BC-5390	71	16.916	0.225	1.33	16.200	17.600	
2026-134	7	DXH500 Ser	149	BC DXH 500	109	13.651	0.161	1.18	13.100	14.200	
2026-134	8	3 ST	84	ABBOTT C-D	14	6.431	0.159	2.47	6.200	6.700	
2026-134	8	3 ST	138	SY KX-21N	10	6.950	2.286	32.89	6.700	7.200	
2026-135	1	Sysmex CBC	132	SYSMEX XS	137	13.084	0.151	1.16	12.600	13.600	
2026-135	1	Sysmex CBC	141	SYSMEX XN	64	13.125	0.129	0.98	12.600	13.700	
2026-135	1	Sysmex CBC	152	Sysmex XN	254	13.104	0.115	0.88	12.600	13.600	
2026-135	2	ACT PENTRA	125	COULTER AC	32	6.361	0.074	1.16	6.100	6.600	
2026-135	2	ACT PENTRA	130	ABX PENTRA	33	6.366	0.092	1.45	6.100	6.600	
2026-135	3	ADVIA 120	116	ADVIA-120	14	5.571	0.059	1.06	5.300	5.800	
2026-135	4	AB-CELL DY	115	ABBOTT C-D	31	13.763	0.196	1.42	13.200	14.300	
2026-135	4	AB-CELL DY	142	EMERALD	17	11.838	0.145	1.23	11.400	12.300	
2026-135	4	AB-CELL DY	153	AB-CEL-RUB	49	13.745	0.176	1.28	13.200	14.300	
2026-135	5	BECTON D	137	B.C DXH	49	12.090	0.157	1.30	11.600	12.600	
2026-135	6	MR Mindray	145	BC-5390	71	13.310	0.147	1.10	12.800	13.800	
2026-135	7	DXH500 Ser	149	BC DXH 500	109	6.312	0.097	1.53	6.100	6.600	
2026-135	8	3 ST	84	ABBOTT C-D	14	18.169	0.414	2.28	17.400	18.900	
2026-135	8	3 ST	138	SY KX-21N	10	16.970	3.597	21.19	16.300	17.600	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
552	WHITE CELL COUNT(WBC	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE	10	%				
2026-131	1	Sysmex CBC	132 SYSMEX XS	137	7.599	0.327	4.30	6.800	8.400
2026-131	1	Sysmex CBC	141 SYSMEX XN	64	7.978	0.146	1.83	7.200	8.800
2026-131	1	Sysmex CBC	152 Sysmex XN	255	7.610	0.209	2.75	6.800	8.400
2026-131	2	ACT PENTRA	125 COULTER AC	32	19.200	0.517	2.69	17.300	21.100
2026-131	2	ACT PENTRA	130 ABX PENTRA	33	19.300	0.567	2.94	17.400	21.200
2026-131	3	ADVIA 120	116 ADVIA-120	14	17.564	0.632	3.60	15.800	19.300
2026-131	4	AB-CELL DY	115 ABBOTT C-D	32	7.963	0.216	2.71	7.200	8.800
2026-131	4	AB-CELL DY	142 EMERALD	17	6.663	0.127	1.90	6.000	7.300
2026-131	4	AB-CELL DY	153 AB-CEL-RUB	48	7.733	0.259	3.35	7.000	8.500
2026-131	5	BECTON D	137 B.C DXH	49	9.120	0.201	2.20	8.200	10.000
2026-131	6	MR Mindray	145 BC-5390	71	8.404	0.200	2.38	7.600	9.200
2026-131	7	DXH500 Ser	149 BC DXH 500	109	18.953	0.447	2.36	17.100	20.800
2026-131	8	3 ST	84 ABBOTT C-D	14	2.908	0.100	3.43	2.600	3.200
2026-132	1	Sysmex CBC	132 SYSMEX XS	137	3.896	0.222	5.71	3.500	4.300
2026-132	1	Sysmex CBC	141 SYSMEX XN	64	4.003	0.143	3.56	3.600	4.400
2026-132	1	Sysmex CBC	152 Sysmex XN	255	3.646	0.142	3.88	3.300	4.000
2026-132	2	ACT PENTRA	125 COULTER AC	32	8.427	0.314	3.72	7.600	9.300
2026-132	2	ACT PENTRA	130 ABX PENTRA	33	8.464	0.213	2.52	7.600	9.300
2026-132	3	ADVIA 120	116 ADVIA-120	14	7.764	0.149	1.92	7.000	8.500
2026-132	4	AB-CELL DY	115 ABBOTT C-D	32	3.087	0.104	3.37	2.800	3.400
2026-132	4	AB-CELL DY	142 EMERALD	17	2.250	0.087	3.85	2.000	2.500
2026-132	4	AB-CELL DY	153 AB-CEL-RUB	48	3.102	0.102	3.29	2.800	3.400
2026-132	5	BECTON D	137 B.C DXH	49	4.263	0.147	3.44	3.800	4.700
2026-132	6	MR Mindray	145 BC-5390	71	3.339	0.090	2.69	3.000	3.700
2026-132	7	DXH500 Ser	149 BC DXH 500	109	7.389	0.192	2.59	6.700	8.100
2026-132	8	3 ST	84 ABBOTT C-D	14	20.669	0.692	3.35	18.600	22.700
2026-133	1	Sysmex CBC	132 SYSMEX XS	137	3.927	0.213	5.42	3.500	4.300

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-133	1	Sysmex CBC	141 SYSMEX XN	64	3.990	0.116	2.90	3.600	4.400	
2026-133	1	Sysmex CBC	152 Sysmex XN	255	3.634	0.120	3.29	3.300	4.000	
2026-133	2	ACT PENTRA	125 COULTER AC	32	19.088	0.567	2.97	17.200	21.000	
2026-133	2	ACT PENTRA	130 ABX PENTRA	33	19.179	0.555	2.89	17.300	21.100	
2026-133	3	ADVIA 120	116 ADVIA-120	14	17.679	0.472	2.67	15.900	19.400	
2026-133	4	AB-CELL DY	115 ABBOTT C-D	32	3.090	0.078	2.51	2.800	3.400	
2026-133	4	AB-CELL DY	142 EMERALD	17	2.225	0.056	2.51	2.000	2.400	
2026-133	4	AB-CELL DY	153 AB-CEL-RUB	48	3.075	0.113	3.66	2.800	3.400	
2026-133	5	BECTON D	137 B.C DXH	49	4.302	0.145	3.37	3.900	4.700	
2026-133	6	MR Mindray	145 BC-5390	71	3.354	0.097	2.88	3.000	3.700	
2026-133	7	DXH500 Ser	149 BC DXH 500	109	18.812	0.456	2.42	16.900	20.700	
2026-133	8	3 ST	84 ABBOTT C-D	14	8.377	0.245	2.93	7.500	9.200	
552 WHITE CELL COUNT(WBC				CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 10 %					
2026-134	1	Sysmex CBC	132 SYSMEX XS	137	20.743	0.729	3.51	18.700	22.800	
2026-134	1	Sysmex CBC	141 SYSMEX XN	64	21.475	0.269	1.25	19.300	23.600	
2026-134	1	Sysmex CBC	152 Sysmex XN	255	21.103	0.422	2.00	19.000	23.200	
2026-134	2	ACT PENTRA	125 COULTER AC	32	8.445	0.310	3.67	7.600	9.300	
2026-134	2	ACT PENTRA	130 ABX PENTRA	33	8.497	0.198	2.33	7.600	9.300	
2026-134	3	ADVIA 120	116 ADVIA-120	14	7.677	0.252	3.28	6.900	8.400	
2026-134	4	AB-CELL DY	115 ABBOTT C-D	32	21.244	0.464	2.19	19.100	23.400	
2026-134	4	AB-CELL DY	142 EMERALD	17	18.500	0.283	1.53	16.700	20.400	
2026-134	4	AB-CELL DY	153 AB-CEL-RUB	48	20.854	0.622	2.98	18.800	22.900	
2026-134	5	BECTON D	137 B.C DXH	49	20.771	0.390	1.88	18.700	22.800	
2026-134	6	MR Mindray	145 BC-5390	71	18.767	0.384	2.04	16.900	20.600	
2026-134	7	DXH500 Ser	149 BC DXH 500	109	7.432	0.211	2.84	6.700	8.200	
2026-134	8	3 ST	84 ABBOTT C-D	14	2.985	0.086	2.89	2.700	3.300	
2026-135	1	Sysmex CBC	132 SYSMEX XS	137	7.636	0.357	4.67	6.900	8.400	
2026-135	1	Sysmex CBC	141 SYSMEX XN	64	7.991	0.184	2.30	7.200	8.800	
2026-135	1	Sysmex CBC	152 Sysmex XN	255	7.613	0.219	2.87	6.900	8.400	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-135	2	ACT PENTRA	125 COULTER AC	32	2.936	0.112	3.83	2.600	3.200
2026-135	2	ACT PENTRA	130 ABX PENTRA	33	2.939	0.092	3.13	2.600	3.200
2026-135	3	ADVIA 120	116 ADVIA-120	14	3.186	0.106	3.33	2.900	3.500
2026-135	4	AB-CELL DY	115 ABBOTT C-D	32	7.894	0.152	1.93	7.100	8.700
2026-135	4	AB-CELL DY	142 EMERALD	17	6.588	0.117	1.77	5.900	7.200
2026-135	4	AB-CELL DY	153 AB-CEL-RUB	48	7.876	0.222	2.82	7.100	8.700
2026-135	5	BECTON D	137 B.C DXH	49	9.151	0.215	2.35	8.200	10.100
2026-135	6	MR Mindray	145 BC-5390	71	8.399	0.184	2.19	7.600	9.200
2026-135	7	DXH500 Ser	149 BC DXH 500	109	2.843	0.087	3.08	2.600	3.100
2026-135	8	3 ST	84 ABBOTT C-D	14	20.777	0.645	3.10	18.700	22.900

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 134 PLATELET COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
553 PLATELET COUNT				CLIA TEST ID #: 815 EVALUATION CRITERIA: TARGET VALUE 25 %					
2026-131	1	SYSMEX CBC	79 SYSMEX XS	136	224.430	10.434	4.65	168.000	281.000
2026-131	1	SYSMEX CBC	87 SYSMEX XN	66	219.769	7.942	3.61	165.000	275.000
2026-131	1	SYSMEX CBC	98 SYSMEX 350	254	217.952	9.821	4.51	163.000	272.000
2026-131	2	ACT5 PENTR	73 COULTER AC	31	456.226	13.860	3.04	342.000	570.000
2026-131	2	ACT5 PENTR	78 ABX PENTRA	33	449.788	16.807	3.74	337.000	562.000
2026-131	3	ADVIA 120	64 ADVIA-120	14	460.786	43.379	9.41	346.000	576.000
2026-131	4	AB- CELL-D	63 ABBOTT C-D	30	277.467	19.390	6.99	208.000	347.000
2026-131	4	AB- CELL-D	88 CELL-DYN E	17	268.176	18.806	7.01	201.000	335.000
2026-131	4	AB- CELL-D	100 ABB.RUBY	49	289.820	15.830	5.46	217.000	362.000
2026-131	5	BECTON D	83 B.C600,800	49	268.184	7.915	2.95	201.000	335.000
2026-131	6	MR Mindray	91 BC-5390	71	262.942	8.573	3.26	197.000	329.000
2026-131	8	3 ST	31 ABBOTT C-D	14	66.077	5.526	8.36	50.000	83.000
2026-131	8	3 ST	84 KX21,300	10	118.400	140.903	119.01	89.000	148.000
2026-131	10	DxH	94 BC DXH 500	108	504.056	25.338	5.03	378.000	630.000

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
553	PLATELET COUNT	CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2026-132	1	SYSMEX CBC	79	SYSMEX XS	136	59.000	4.004	6.79	44.000	74.000	
2026-132	1	SYSMEX CBC	87	SYSMEX XN	66	45.788	2.847	6.22	34.000	57.000	
2026-132	1	SYSMEX CBC	98	SYSMEX 350	254	46.898	2.894	6.17	35.000	59.000	
2026-132	2	ACT5 PENTR	73	COULTER AC	31	246.387	8.412	3.41	185.000	308.000	
2026-132	2	ACT5 PENTR	78	ABX PENTRA	33	246.303	11.302	4.59	185.000	308.000	
2026-132	3	ADVIA 120	64	ADVIA-120	14	230.143	20.942	9.10	173.000	288.000	
2026-132	4	AB- CELL-D	63	ABBOTT C-D	30	82.103	7.411	9.03	62.000	103.000	
2026-132	4	AB- CELL-D	88	CELL-DYN E	17	92.647	9.474	10.23	69.000	116.000	
2026-132	4	AB- CELL-D	100	ABB.RUBY	49	82.898	5.100	6.15	62.000	104.000	
2026-132	5	BECTON D	83	B.C600,800	49	87.041	3.528	4.05	65.000	109.000	
2026-132	6	MR Mindray	91	BC-5390	71	48.971	2.610	5.33	37.000	61.000	
2026-132	8	3 ST	31	ABBOTT C-D	14	375.615	44.419	11.83	282.000	470.000	
2026-132	8	3 ST	84	KX21,300	10	404.500	53.675	13.27	303.000	506.000	
2026-132	10	DxH	94	BC DXH 500	108	256.778	13.171	5.13	193.000	321.000	
2026-133	1	SYSMEX CBC	79	SYSMEX XS	136	58.963	3.911	6.63	44.000	74.000	
2026-133	1	SYSMEX CBC	87	SYSMEX XN	66	45.738	2.426	5.30	34.000	57.000	
2026-133	1	SYSMEX CBC	98	SYSMEX 350	254	46.480	2.925	6.29	35.000	58.000	
2026-133	2	ACT5 PENTR	73	COULTER AC	31	452.323	13.915	3.08	339.000	565.000	
2026-133	2	ACT5 PENTR	78	ABX PENTRA	33	443.485	14.598	3.29	333.000	554.000	
2026-133	3	ADVIA 120	64	ADVIA-120	14	463.714	44.168	9.52	348.000	580.000	
2026-133	4	AB- CELL-D	63	ABBOTT C-D	30	81.069	7.451	9.19	61.000	101.000	
2026-133	4	AB- CELL-D	88	CELL-DYN E	17	92.588	9.531	10.29	69.000	116.000	
2026-133	4	AB- CELL-D	100	ABB.RUBY	49	81.320	5.669	6.97	61.000	102.000	
2026-133	5	BECTON D	83	B.C600,800	49	87.939	2.888	3.28	66.000	110.000	
2026-133	6	MR Mindray	91	BC-5390	71	49.420	2.150	4.35	37.000	62.000	
2026-133	8	3 ST	31	ABBOTT C-D	14	192.769	16.962	8.80	145.000	241.000	
2026-133	8	3 ST	84	KX21,300	10	240.500	93.252	38.77	180.000	301.000	
2026-133	10	DxH	94	BC DXH 500	108	504.140	22.926	4.55	378.000	630.000	

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS			LABS	VALUE	DEVIATION	CV	LOW	HIGH
553	PLATELET COUNT	CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %								
2026-134	1	SYSMEX CBC	79	SYSMEX XS		136	398.679	16.733	4.20	299.000	498.000
2026-134	1	SYSMEX CBC	87	SYSMEX XN		66	420.712	14.490	3.44	316.000	526.000
2026-134	1	SYSMEX CBC	98	SYSMEX 350		254	417.133	16.458	3.95	313.000	521.000
2026-134	2	ACT5 PENTR	73	COULTER AC		31	246.323	9.285	3.77	185.000	308.000
2026-134	2	ACT5 PENTR	78	ABX PENTRA		33	245.970	10.001	4.07	184.000	307.000
2026-134	3	ADVIA 120	64	ADVIA-120		14	231.786	25.228	10.88	174.000	290.000
2026-134	4	AB- CELL-D	63	ABBOTT C-D		30	515.379	30.675	5.95	387.000	644.000
2026-134	4	AB- CELL-D	88	CELL-DYN E		17	506.529	32.930	6.50	380.000	633.000
2026-134	4	AB- CELL-D	100	ABB.RUBY		49	527.160	24.963	4.74	395.000	659.000
2026-134	5	BECTON D	83	B.C600,800		49	500.375	15.267	3.05	375.000	625.000
2026-134	6	MR Mindray	91	BC-5390		71	554.657	16.879	3.04	416.000	693.000
2026-134	8	3 ST	31	ABBOTT C-D		14	63.923	4.582	7.17	48.000	80.000
2026-134	8	3 ST	84	KX21,300		10	88.500	57.639	65.13	66.000	111.000
2026-134	10	DxH	94	BC DXH 500		108	255.741	14.963	5.85	192.000	320.000
2026-135	1	SYSMEX CBC	79	SYSMEX XS		136	223.163	12.815	5.74	167.000	279.000
2026-135	1	SYSMEX CBC	87	SYSMEX XN		66	218.523	9.025	4.13	164.000	273.000
2026-135	1	SYSMEX CBC	98	SYSMEX 350		254	217.729	10.919	5.02	163.000	272.000
2026-135	2	ACT5 PENTR	73	COULTER AC		31	72.533	5.058	6.97	54.000	91.000
2026-135	2	ACT5 PENTR	78	ABX PENTRA		33	71.970	4.079	5.67	54.000	90.000
2026-135	3	ADVIA 120	64	ADVIA-120		14	50.571	6.662	13.17	38.000	63.000
2026-135	4	AB- CELL-D	63	ABBOTT C-D		30	282.933	22.993	8.13	212.000	354.000
2026-135	4	AB- CELL-D	88	CELL-DYN E		17	270.235	19.774	7.32	203.000	338.000
2026-135	4	AB- CELL-D	100	ABB.RUBY		49	288.560	17.121	5.93	216.000	361.000
2026-135	5	BECTON D	83	B.C600,800		49	269.000	5.803	2.16	202.000	336.000
2026-135	6	MR Mindray	91	BC-5390		71	264.843	8.756	3.31	199.000	331.000
2026-135	8	3 ST	31	ABBOTT C-D		14	352.000	62.728	17.82	264.000	440.000
2026-135	8	3 ST	84	KX21,300		10	385.200	106.617	27.68	289.000	482.000
2026-135	10	DxH	94	BC DXH 500		108	76.860	5.120	6.66	58.000	96.000

Participant Summary

MONTH 3 OF YEAR 2026

SPEC: 20 HEMATOLOGY SUB: 75 BODY FLUID GRP: 145 BODY FLUID CELL COU.

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
159	BF RED CELL COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
	2026-171				36	0.600	0.763	127.24	0	3.000
	2026-172				36	1029.278	103.459	10.05	719.000	1340.000
	2026-173				36	1050.057	104.942	9.99	735.000	1365.000
	2026-174				36	0.314	0.464	147.71	0	2.000
	2026-175				36	1047.286	85.142	8.13	785.000	1309.000
160	BF WHITE CELL COUNT									
	2026-171				35	4.800	1.720	35.84	0.000	10.000
	2026-172				35	323.206	27.889	8.63	240.000	407.000
	2026-173				35	328.206	37.606	11.46	215.000	441.000
	2026-174				35	5.143	2.016	39.21	0	11.000
	2026-175				35	326.912	42.621	13.04	199.000	455.000

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 30 IMMUNOHEMATOLOGY		SUB: 80 ABO-RH				GRP: 150 ABO-RH							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
083 ABO GROUP													
2026-181				001 003	001 003		001 - A	76	75	76	100		
2026-181				001 003	001 003		002 - A1	76	1	76	100		
2026-182				004 004	004 004		004 - B	76	76	76	100		
2026-183				008 008	008 008		008 - O	76	76	76	100		
2026-184				008 008	008 008		008 - O	76	76	76	100		
2026-185				008 008	008 008		008 - O	76	76	76	100		
126 RH TYPE													
2026-181				001 003	001 003		001 - Rh+	76	76	76	100		
2026-182				001 003	001 003		001 - Rh+	76	76	76	100		
2026-183				001 003	001 003		001 - Rh+	76	76	76	100		
2026-184				003 004	003 004		003 - Rh-Du np	76	7	76	100		
2026-184				003 004	003 004		004 - Rh-	76	69	76	100		
2026-185				003 004	003 004		003 - Rh-Du np	76	7	76	100		
2026-185				003 004	003 004		004 - Rh-	76	69	76	100		

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 160 Indirect COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2026-191				001 001	001 001		001 - NEGATIVE	59	59	59	100
2026-192				001 001	001 001		001 - NEGATIVE	59	59	59	100
2026-193				002 002	002 002		001 - NEGATIVE	59	1	58	0
2026-193				002 002	002 002		002 - POSITIVE	59	58	58	100
2026-194				002 002	002 002		002 - POSITIVE	59	59	59	100
2026-195				001 001	001 001		001 - NEGATIVE	59	59	59	100

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2026-271	001 Poly AHG	001 Gel		002 004	002 004		002 - 2+	16	2	16	100
2026-271	001 Poly AHG	001 Gel		002 004	002 004		003 - 3+	16	13	16	100
2026-271	001 Poly AHG	001 Gel		002 004	002 004		004 - 4+	16	1	16	100
2026-271	001 Poly AHG	002 Tubo		002 004			001 - Negativo	32	1	31	0
2026-271	001 Poly AHG	002 Tubo		002 004			002 - 2+	32	26	31	100
2026-271	001 Poly AHG	002 Tubo		002 004			003 - 3+	32	5	31	100
2026-271	002 MnoAnt-IgG	001 Gel		002 004	002 004		003 - 3+	17	14	17	100
2026-271	002 MnoAnt-IgG	001 Gel		002 004	002 004		004 - 4+	17	3	17	100
2026-271	002 MnoAnt-IgG	002 Tubo			002 004		002 - 2+	14	11	14	100
2026-271	002 MnoAnt-IgG	002 Tubo			002 004		003 - 3+	14	3	14	100

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2026-272	001 Poly AHG	001 Gel			002 004		002 - 2+	16	3	16	100
2026-272	001 Poly AHG	001 Gel			002 004		003 - 3+	16	12	16	100
2026-272	001 Poly AHG	001 Gel			002 004		004 - 4+	16	1	16	100
2026-272	001 Poly AHG	002 Tubo		002 004	002 004		002 - 2+	32	28	32	100
2026-272	001 Poly AHG	002 Tubo		002 004	002 004		003 - 3+	32	4	32	100
2026-272	002 MnoAnt-IgG	001 Gel			002 004		002 - 2+	17	1	17	100
2026-272	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	17	13	17	100
2026-272	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	17	3	17	100
2026-272	002 MnoAnt-IgG	002 Tubo			002 004		002 - 2+	14	11	14	100
2026-272	002 MnoAnt-IgG	002 Tubo			002 004		003 - 3+	14	3	14	100
2026-273	001 Poly AHG	001 Gel		002 004	002 004		002 - 2+	16	2	16	100
2026-273	001 Poly AHG	001 Gel		002 004	002 004		003 - 3+	16	13	16	100
2026-273	001 Poly AHG	001 Gel		002 004	002 004		004 - 4+	16	1	16	100
2026-273	001 Poly AHG	002 Tubo		002 004			002 - 2+	32	26	32	100
2026-273	001 Poly AHG	002 Tubo		002 004			003 - 3+	32	6	32	100
2026-273	002 MnoAnt-IgG	001 Gel		002 004	002 004		003 - 3+	17	14	17	100
2026-273	002 MnoAnt-IgG	001 Gel		002 004	002 004		004 - 4+	17	3	17	100
2026-273	002 MnoAnt-IgG	002 Tubo		002 004	002 004		002 - 2+	14	12	14	100
2026-273	002 MnoAnt-IgG	002 Tubo		002 004	002 004		003 - 3+	14	2	14	100
2026-274	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	16	16	16	100
2026-274	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2026-274	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	16	16	16	100
2026-274	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	14	14	14	100
2026-275	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	16	16	16	100
2026-275	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-275	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	16	16	16	100	
2026-275	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	14	14	14	100	

SPE: 30 IMMUNOHEMATOLOGY				SUB: 100 COMPATIBILITY TESTING				GRP: 170 COMPATIBILITY TEST.				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
085 COMPATIBIL. TESTING												
2026-201				002 002	002 002		002 - INCOMPATIB	39	39	39	100	
2026-202				002 002	002 002		002 - INCOMPATIB	39	39	39	100	
2026-203							001 - COMPATIBLE	39	27	39	0	
2026-203							002 - INCOMPATIB	39	12	39	0	
2026-204				001 001	001 001		001 - COMPATIBLE	39	39	39	100	
2026-205				001 001	001 001		001 - COMPATIBLE	39	39	39	100	

Participant Summary

MONTH 3 OF YEAR 2026

SPE: 30 IMMUNOHEMATOLOGY		SUB: 110 ANTIBODY IDENTIFICATION				GRP: 180 ANTIBODY IDENT.					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# LABS ANSW	# "SF" LABS	Score
086 ANTIBODY IDENT.TEST.											
2026-201				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2026-202				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2026-203				018 018	018 018		018 - Anti Fy a	10	10	10	100
2026-204				007 007	007 007		007 - Anti E	10	10	10	100
2026-205				001 001	001 001		001 - UN. ANT.ND	10	10	10	100